Recent genetic tools have allowed researchers to visualize and manipulate memory traces (i.e., engrams) in small brain regions. However, the ultimate goal is to visualize memory traces across the entire brain in order to better understand how memories are stored in neural networks and how multiple memories may coexist. Intact tissue clearing and imaging is a new and rapidly growing area of focus that could accomplish this task. Here, we utilized the leading protocols for whole- 
| I N TR ODU C TI ON
Visualization of molecular tissue structures is an essential tool in many biological and medical disciplines. Tissue visualization is made possible by immunolabeling of molecular structures. However, the application of these techniques has historically been limited to thin tissue sections due to the inability of photons and molecular labels to penetrate deep tissue. Moreover, tissue-slicing techniques often compromise the structural integrity of the tissue and the molecular circuitry within it. To avoid these problems and instead image intact tissue without slicing, the molecules that prevent photons and antibodies from deep tissue penetration-lipids-must be cleared from the tissue.
To accomplish this, several techniques have been developed in recent years: Scale (Hama et al., 2011) , ScaleS (Hama et al., 2015) , 3DISCO (Ert€ urk et al., 2012; Ert€ urk, Lafkas, & Chalouni, 2014) , ClearT2 (Kuwajima et al., 2013) , SeeDB (Ke, Fujimoto, & Imai, 2013) , CLARITY (Chung et al., 2013; Tomer, Ye, Hsueh, & Deisseroth, 2014) , PACT (Yang et al., 2014) , CUBIC (Susaki et al., 2014 (Susaki et al., , 2015 , iDISCO (Renier et al., 2014) , and SWITCH (Murray et al., 2015) . By optimizing for time, cost, preservation of structural integrity, and endogenous and/or exogenous fluorescence, these techniques render the intact tissue transparent while preserving fine-wiring and molecular structures.
These methods grant unprecedented access to neural activity, neural projections, and gene expression across the entire brain (Belle et al., 2014; Kim et al., 2015; Renier et al., 2016; Wang et al., 2015) . The brain-wide insights offered by tissue clearing are particularly important for the study of memory traces or engrams. Through extensive investigation in recent years, memory traces have been found in several cross-brain regions, including the hippocampus (HPC) and various neocortical regions (Bonnici, Chadwick, & Maguire, 2013; Denny et al., 2014; Tayler, Tanaka, Reijmers, & Wiltgen, 2013; Wiltgen, Sanders, Anagnostaras, Sage, & Fanselow, 2006; Wiltgen and Silva, 2007; Wiltgen et al., 2010) . However, much is still unknown about the mechanisms by which memories are formed and retrieved, or how memories are stored together across different brain regions. To better study memories, we previously developed an indelible system, the ArcCreER T2 transgenic mouse (Denny et al., 2014) , that allows for comparison between permanently labeled EYFP 1 neurons activated during learning and recently labeled Arc 1 or c-Fos 1 cells activated during memory retrieval. By using this mouse line in combination with a clearing technique that allows imaging of the entire mouse brain, the crossbrain circuitry of memory traces can be studied. Therefore, such a clearing technique must allow for successful, thorough, and precise antibody penetration for EYFP and Arc/c-Fos.
In this study, we thoroughly tested and modified clearing methods using the aforementioned clearing protocols for immunolabeling of EYFP and Arc/c-Fos in mm-thick tissue slices from the ArcCreER T2 mice. iDISCO and CUBIC were superior to CLARITY and PACT for labeling Arc and c-Fos; however, without modification, none of these methods yielded satisfactory labeling. To overcome this, we: (1) improved the solutions used during iDISCO immunolabeling and clearing to decrease fluorescence quenching; (2) identified a set of antibodies termed nanobodies that achieved relatively uniform labeling; and (3) modified incubation periods, antibodies, and antibody concentrations.
Our results show that a modified protocol based on CUBIC with
Reagent-1A, which we term CUBIC with Reagent-1A*, achieves satisfactory co-labeling. Together, these results provide optimized clearing protocols that yield representative EYFP fluorescence and Arc/c-Fos immunolabeling for use in memory trace studies.
| M A TE RI A L S A ND M E TH ODS

| Mice
The ArcCreER T2 mice were generated and genotyped as previously described (Denny et al., 2014) . ArcCreER
T2
(1) mice were bred with ROSA26-CAG-stop flox -ChR2(H134R)-EYFP (Ai32) (Madisen et al., 2012) . ArcCreER T2 mice were also bred with a Rosa26-LSL-H2B-mCherry line (Peron, Freeman, Iyer, Guo, & Svoboda, 2015 
| Contextual fear conditioning (CFC)
ArcCreER T2 mice were administered a CFC procedure as previously described (Denny et al., 2014) . For context exposure, mice were reexposed to the training context and euthanized 1 h later in order for optimal Arc or c-Fos protein expression.
| 4-Hydroxytamoxifen (4-OHT)
Five hours before CFC, ArcCreER T2 mice were injected with 2 mg of 4-OHT as previously described (Cazzulino, Martinez, Tomm, & Denny, 2016) . ArcCreER T2 x H2B-mCherry mice were injected with vehicle (Veh) or 1 mg of 4-OHT.
| Brain processing
Mice were transcardially perfused with 4% paraformaldehyde (PFA).
Brains were further fixed in 4% PFA at 4 8C overnight. Next, brains
were cut into half-brain samples or into 4-mm-, 2-mm-, or 1-mm-thick coronal slices using a manual brain cutter. All prescreening experiments were performed on 35-or 100-lm thick coronal slices, which were obtained by immersing whole brains in 4% PFA overnight, then in 30% sucrose at 4 8C for 3 days, followed by snap-freezing in OCT medium and slicing on a Leica CM3050 cryostat.
| Antibodies and nanobodies
Antibody and nanobody information is summarized in the Supporting Information and in Supporting Information Table S1 .
| iDISCO-based screening of thirty-five lm-thick sections
Floating 35-lm-thick sections screened for nanobody compatibility with iDISCO (Renier et al., 2014 ) underwent a 2.5 h methanol (MeOH) dehydration sequence, followed by a bleaching step for 10 min. Samples screened for compatibility with various organic solvents underwent a 2.5 h dehydration sequence. Samples undergoing an organic solvent-free pretreatment (referred to here as iDISCO without MeOH)
were incubated in a detergent mixture for 2.5 h. Control samples were incubated in 1X phosphate-buffered saline (PBS) for 2.5 h. Finally, all samples were washed in 0.2% phosphate-buffered saline with Tween-20 (PBST) 3 times for 10 min each. For EYFP immunohistochemistry, samples were blocked for 2 h, washed in 1X PBS/0.2% Tween-20 with 10 lg mL 21 heparin (PTwH) three times for 10 min each, and then incubated in primary antibody dilutions in PTwH/3% normal donkey serum (NDS) for 48 h at 4 8C. Samples were washed again in PTwH three times for 10 min each, placed in secondary antibody dilutions in PTwH/3% normal donkey serum (NDS) for 2 h, and then washed in PTwH three times for 10 min each before mounting and imaging. All steps except the primary antibody incubation were performed at room temperature (RT).
| iDISCO
The iDISCO protocol was followed as previously described (Renier et al., 2014) . Briefly, prior to whole antibody immunolabeling, 4-mmthick tissue slices were permeabilized by a MeOH pretreatment step.
Samples labeled with the anti-GFP nanobody were pretreated with an organic solvent-free protocol, consisting of a series of incubations in detergents (iDISCO without MeOH) (Renier et al., 2014) . Next, samples were immunolabeled with 2 mL of primary antibody or nanobody mixture for 4-5 days at 37 8C, followed by 1 day of washing at RT. Samples were immunolabeled with 2 mL of secondary antibody mixture for 4 days at 37 8C.
To test if iDISCO quenches endogenous EYFP fluorescence, 4-mm-thick sections were treated only with clearing steps of the iDISCO protocol. After 4% PFA fixation, samples were washed in 1X PBS three times for 1 h each, and dehydrated with 50% THF (in ddH 2 O), 80%
THF, 100% THF, and 100% THF as described in the original iDISCO protocol (Renier et al., 2014) . To test the effect of other organic dehydration solvents, THF was replaced with MeOH, tert-Butanol, or buffered tert-Butanol. After dehydration, samples were further cleared with DCM and DBE as previously described (Renier et al., 2014) . To decrease tissue oxidation, all organic solvent steps were performed under vacuum at RT. tert-Butanol was buffered to pH 9.5 using triethylamine (3EtN) (1:118 dilution). We also pretreated samples with the iDISCO without MeOH procedure.
2.8 | CUBIC with reagent-1A/CUBIC with reagent-1A*
CUBIC with Reagent-1A protocol was previously reported to optimize endogenous fluorescence preservation from reporter proteins after tissue clearing (Susaki and Ueda, 2016) . One-mm thick tissue slices were treated with the same tissue treatment, immunolabeling (Cy3 secondary antibody for Arc immunolabeling), and clearing procedure as in the original CUBIC with Reagent-1A protocol, with its decreased amount of Triton (10% weight (wt)), Urea (10% wt), and Quadrol (5% wt). To achieve more uniform thick-tissue Arc immunolabeling, we made a series of modifications that we now term CUBIC with Reagent-1A*.
We utilized a lower dilution factor of the rabbit anti-Arc primary antibody (1:500) and a 5-day incubation period for the primary and sec- , a z step of 10-100 lm, and at 1 f s
21
. Several fields of view were stitched together to form tiled images by using an automated stage as well as the tiling function and algorithm of the LAS X software.
| Image processing and analysis
Maximum projections of z stacks were performed using ImageJ (NIH, https://imagej.nih.gov/ij/, RRID:SCR_003070). An unpaired t test determined statistical differences in average image intensities between experimental groups. CellProfiler (http://cellprofiler.org) was used for automated cell counting.
| RE S U L TS
3.1 | ArcCreER T2 mice allow for memory trace labeling in mm-thick tissue slices
The cross-brain circuitry of memory traces can be studied by utilizing our indelible labeling system, the ArcCreER T2 (Denny et al., 2014 Although counting cells with dendritic labeling is possible, we hypothesized utilizing a line with a nuclear tag rather than a dendritic label may better facilitate automated counting. Therefore, we also bred the ArcCreER T2 mice with H2B-mCherry mice (Peron et al., 2015) , We next determined that automated counting of EYFP 1 and Arc/ c-Fos 1 cells is possible using the ArcCreER T2 x ChR2-EYFP mice (Supporting Information Figure S1 ), suggesting that it is an appropriate model for labeling and automated quantification of whole-brain memory traces.
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| CLARITY and PACT do not permit uniform arc immunolabeling or preserve endogenous EYFP fluorescence
Intact-tissue immunolabeling for EYFP and Arc was first attempted on 4-mm mouse brain tissue sections using CLARITY (Tomer et al., 2014) .
CLARITY, a hydrogel embedding clearing method, clears the brain in five main steps: (1) fixation, (2) hydrogel embedding, (3) lipid clearing with SDS detergent and electrophoresis tissue clearing (ETC), (4) immunolabeling, and (5) refractive index (RI) matching with FocusClear (Supporting Information Figure S2a ). As expected, brains cleared using CLARITY become relatively clear initially and then turn opaque when released from the clearing state prior to RI matching homogenization (Supporting Information Figure S2b ). To improve transparency, hydrogel concentration was varied from 4% PFA/4% acrylamide/0.025% bisacrylamide to 4% PFA/1% acrylamide/0.025% bis-acrylamide (Supporting Information Figure S2c ). While optimal clearing was achieved with a 4% PFA/2% acrylamide/0.025% bis-acrylamide hydrogel concentration and ETC for 5 days at 37 8C and 0.6-0.7 A (Supporting Information Figure S2d ), no deep tissue Arc immunolabeling was observed with this protocol, as the antibody remained in the tissue periphery (Supporting Information Figure S2e ).
In an additional attempt to improve transparency, a modified CLARITY procedure was performed on 4-mm-thick tissue slices as previously described (Epp et al., 2015) . A 3% PFA/3% acrylamide/0.025% bis-acrylamide hydrogel concentration was utilized, and ETC was performed first for 5 days at 37 8C and 0.78 A, and next for 1 day at 50 8C and 0.78 A (Supporting Information Figure S3a ). However, samples that were processed using this ETC procedure showed no improved transparency or integrity compared to CLARITY and showed quenched endogenous EYFP fluorescence compared with samples that were passively cleared (Supporting Information Figure S3b ,c). We again varied the hydrogel concentrations in order to potentially preserve EYFP fluorescence, but there was still no fluorescence remaining post-clearing (Supporting Information Figure S2d ,e). These data indicate that the modified CLARITY protocol does not preserve endogenous EYFP fluorescence in the ArcCreER T2 x ChR2-EYFP mice.
PACT (Yang et al., 2014) , another hydrogel embedding clearing method, was also screened, but exhibited unsatisfactory preservation of tissue integrity (i.e., greatly distorted the tissue) and did not allow for Arc or GFP immunolabeling (Supporting Information Figure S4 ). It also quenched the endogenous EYFP fluorescence signal (data not shown).
In summary, these data indicate that CLARITY and PACT are not ideal clearing methods for preserving endogenous EYFP fluorescence or for uniform immunolabeling in the ArcCreER T2 x ChR2-EYFP mice. 
| Strategies for improving EYFP immunolabeling in iDISCO
Two aspects of the iDISCO pipeline were hypothesized to improve deep-tissue EYFP immunolabeling: (1) the amount or size of the antibody, and (2) the organic solvents used for tissue dehydration. First, we tested if the GFP "edge effect" could be resolved by optimizing the anti-GFP antibody concentration (Supporting Information Figure S6 ).
While the GFP "edge effect" was more pronounced at higher antibody concentrations, changes in antibody concentration did not lead to any improvements in deep-tissue EYFP immunolabeling. This is in contrast to the Arc antibody, for which higher concentrations produced better labeling.
We then tested if the "edge effect" was a result of the GFP antibody being too large to penetrate deep tissue and instead accumulating on the brain's periphery. To test this, we utilized a smaller-sized alternative: a GFP nanobody (Fridy et al., 2014) , which functions as the isolated binding region of the antibody (Figure 3a,b) . Thirty-five lm-thick sections stained with GFP nanobody exhibited significantly greater fluorescence intensity than unlabeled sections, but significantly lower fluorescence intensity than whole-antibody labeled sections (ANOVA, F (2,21) 5 157.916, p < 0.0001) (Figure 3c -f). Despite this intensity difference, the nanobody yielded robust staining in ArcCreER T2 x ChR2-EYFP sections.
Because the binding properties of some antibodies are affected by tissue dehydration using organic solvents such as MeOH, we tested whether the nanobody was compatible with the iDISCO MeOH dehydration step prior to immunolabeling. When the thin tissue sections were dehydrated in MeOH, GFP nanobody staining was lost, indicating that MeOH negatively impacts nanobody labeling (Figure 3g,h) . In summary, these experiments suggest that if the GFP IgY antibody is indeed too large to penetrate deep tissue, the smaller GFP nanobody may be a viable alternative, but will require using a dehydration solvent different than MeOH.
3.5 | Improving dehydration solvents for compatibility with the GFP nanobody
We identified three solutions as alternatives to MeOH in the dehydration step of the iDISCO protocol (Figure 4a ). First, we selected a detergent-based solution offered by Renier et al. (2014) for use with
MeOH-incompatible antibodies (referred to here as iDISCO without MeOH). We also selected tert-Butanol and THF, as they appear to be less harsh on organic tissue (Schwarz et al., 2015) . Next, we assessed the intensity of GFP nanobody and GFP whole antibody staining in 35- Buffering organic solvents has also been shown to improve fluorescent labeling (Schwarz et al., 2015) . Therefore, we assessed the intensity of GFP nanobody and GFP whole antibody labeling in 35-lmthick tissue sections that were dehydrated with buffered (to pH 9.5) tert-Butanol (Figure 4q-s) , showing that buffered tert-Butanol did improve GFP nanobody labeling compared to unbuffered tert-Butanol (Figure 4n-p) . Based on these results, the iDISCO without MeOH solutions and buffered tert-Butanol were identified as nanobodycompatible alternatives to the MeOH dehydration step in the iDISCO protocol.
We tested the validity of these results on thick tissues by treating 4-mm-thick tissue sections with this modified iDISCO protocol; MeOH in the preimmunolabeling dehydration step was replaced with either iDISCO without MeOH solutions or buffered tert-Butanol ( Figure 5 ), labeling was performed with GFP nanobody, and the top 100 lm of tissue was imaged both immediately after immunolabeling (preclearing) and after clearing (postclearing) (Figure 5a-d) . GFP nanobody labeling was observed only in the tissue treated with the iDISCO without MeOH solutions (Figure 5d ), suggesting that that the longer dehydration with buffered tert-Butanol negatively affects GFP nanobody binding. Moreover, there was significant autofluorescence seen following the buffered tert-Butanol procedure compared to the iDISCO without 
| iDISCO solvents increase autofluorescence and quench endogenous EYFP fluorescence
Because satisfactory EYFP and Arc/c-Fos coimmunolabeling could not be achieved with any of the aforementioned protocols, we asked whether we could achieve satisfactory signal from endogenous EYFP fluorescence, which has not been previously reported using the iDISCO technique (Renier et al., 2014) . To test this, 4-mm-thick tissue sections were treated with the fixation and clearing steps of the iDISCO protocol and imaged before (in 1X PBS) and after clearing (in DBE) 3.7 | CUBIC preserves endogenous EYFP fluorescence, but yields unsatisfactory arc immunolabeling
To identify a clearing protocol that preserves endogenous EYFP fluorescence in ArcCreER T2 x ChR2-EYFP tissue, we treated 4-mm-thick tissue sections with CUBIC (Susaki et al., 2014 (Susaki et al., , 2015 . CUBIC with Reagent-1A* also permitted c-Fos immunolabeling in a 1-mm-thick tissue section (Supporting Information Figure S11 ). In comparison, organic solvent clearing, such as iDISCO and the recently developed uDISCO (Pan et al., 2016 ) (Supporting Information Figure   S12 ), did not preserve endogenous EYFP fluorescence in our mouse line. These data suggest that the CUBIC with Reagent-1A* is the best clearing technique to utilize with the ArcCreER T2 x ChR2-EYFP mouse model for preserving endogenous EYFP signal and for allowing Arc immunolabeling throughout the tissue. shown that these methods efficiently clear whole brains with relatively sparsely expressed antigens and reporters (Renier et al., 2014 Liebmann et al., 2016) . However, thick-tissue immunolabeling of densely expressed antigens, such as in ArcCreER T2 x ChR2-EYFP mice brains, is challenging, an issue that has been recognized in recent literature (Murray et al., 2015) . We believe the original clearing protocols are tremendously useful, but our results show that they are not optimized for studying whole-brain memory traces in densely labeled lines, such as in the ArcCreER T2 x ChR2-EYFP mice.
| D ISC USSION
In iDISCO-treated mm-thick tissue slices, Arc antibodies stained uniformly, but GFP staining did not fully penetrate the tissue, resulting in an "edge effect." The observed "edge effect" resulted from the dense cortical EYFP label characteristic of the ArcCreER T2 x ChR2-EYFP line, making thick-tissue antibody penetration and uniform labeling more difficult than in other mouse lines typically used for iDISCO studies, which have less dense cortical labeling (Liebmann et al., 2016; Renier et al., 2014) . To resolve this problem and allow GFP staining, several modifications were piloted, including modifications of (1) antibodies and (2) organic solvents used for dehydrating, fixing, and clearing. As an antibody alternative, a GFP nanobody was piloted (Fridy et al., 2014) , which stained uniformly but with significantly less intensity than a GFP when treated with various organic solvents (Pan et al., 2016; Schwarz et al., 2015) . (Herskovits, Gadegbeku, & Jaillet, 1970; Schwarz et al., 2015) .
These studies also found that tert-Butanol preserves protein fluorescence significantly better than MeOH and other alternatives, which aligns with our thin section results. Likewise, studies showing that THF and MeOH clear lipids and water more aggressively than tert-Butanol may explain the poor nanobody penetration in thick sections treated with tert-Butanol (Ert€ urk et al., 2012 (Ert€ urk et al., , 2014 Herskovits et al., 1970; Schwarz et al., 2015) . Nevertheless, tert-Butanol is still an organic solvent, so the possibility that it, too, like MeOH and THF, may not be gentle enough to preserve nanobody labeling remains. Unlike tertButanol, the iDISCO without MeOH solutions preserved nanobody fluorescence in thick sections. However, the nanobody labeling was diffuse, and determining co-labeling when the tissue was costained with
Arc was infeasible.
A recent whole-brain clearing and imaging technique, uDISCO, champions the use of tert-Butanol as a dehydration solvent for preserving endogenous fluorescence from reporter proteins (Pan et al., 2016) . We piloted this technique as well to determine if endogenous EYFP fluorescence is sufficiently preserved to allow detection of 
